Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patientsMaria Grazia Bernengo, M. T. Fierro, Alessandra Comessatti et al.|Haematologica|2007Cited by 175
Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With DupilumabFrancesco Leo, M. Ortoncelli|International Journal of Dermatology|2026Cited by 0